

## ORIGINAL ARTICLE - PUBLIC HEALTH

## POST COVID SEQUELAE AMONG PEOPLE INFECTED WITH COVID-19 IN TAMIL NADU – A CROSS SECTIONAL STUDY

*Sudharshini Subramaniam* <sup>(1)</sup>, *Avudaiselvi Rathinasamy* <sup>(2)</sup>, *Anandan Mohan* <sup>(2)</sup>,  
*Palani Sampath* <sup>(2)</sup>, *Parthipan Kuarasamy* <sup>(2)</sup>, *Selvavinayagam T S* <sup>(2)</sup>

(1) Institute of Community Medicine, Madras Medical College

(2) Directorate of Public Health & Preventive Medicine, Chennai

## Abstract

**BACKGROUND :** Tamil Nadu witnessed three pandemic peaks since the first COVID-19 case on March 7, 2020. Long-term effects, termed long COVID, persist with various symptoms and organ involvement. Despite the Indian government's guidelines, there's limited data on long COVID among survivors in India. This study was done to find the burden of post covid symptoms among individuals who tested positive for Covid-19 between March 2020 and February 2022 in Tamil Nadu, other than Chennai.

**METHODS :** A cross-sectional study in Tamil Nadu, excluding Chennai, was conducted among 1673 COVID-19 cases in June 2023 who were selected by stratified random sampling, stratified by age groups. Trained health staff gathered data using a semi-structured questionnaire, defining persistent post-COVID-19 symptoms as lasting more than 12 weeks. Data was entered in Excel and analysed using JASP software.

**RESULTS :** Among 1673 patients approached, 380 participants could not be contacted even after multiple attempts. Among the rest 1293 patients, seventy three patients(5.6%) were reported to have died. The overall prevalence of persistent post Covid symptoms was 21.3%(95% CI -19.04% - 23.72%). The most common symptom reported was loss of appetite and persistent fatigue. there is no significant association between gender, age group, pandemic wave, number of episodes of covid infection, covid vaccination and persistent post covid symptoms. However, hospitalisation, oxygen requirement, ventilatory support requirement, lung involvement and presence of any comorbidities was significantly associated with persistent post covid syndrome.

**CONCLUSION :** Targeted interventions for individuals with a history of severe COVID-19, pre-existing comorbidities, and specific post-COVID complications, healthcare systems can better support the holistic recovery and well-being of those affected by the long-term effects of the virus.

**KEY WORDS :** Long Covid, Post Covid, Persistent Post Covid Symptoms

## INTRODUCTION

Tamil Nadu had the 1st case of Covid -19 on March 7th, 2020, ever since then there had been an increase in the number of cases with the state having witnessed 3 peaks of the pandemic in the year 2020 ,2021and 2022. There are evidences which states that Covid -19 does not end with acute infection, but continue to have long term effects affecting multiple organs. In a meta-analysis done by Leon's et al, reported more than 50 different long-term effects of Covid -19 with the time duration ranging from 14 to 110 days post viral infection. The meta-analysis reported that 80% of the infected people continued to have at least one effect even after 2 weeks of the infection. The 5 most common symptoms reported was fatigue, headache, attention deficit, hair loss and dyspnoea. But no studies from India was included in the meta-analysis. WHO had reported that the time duration how long the post covid 19 condition also called as long Covid or Long Haulers persist as non-predictable.<sup>1</sup> In a recent prospective study conducted in China reported that 55% of Covid -19 survivors had long Covid effects at the end of 2 years, though there was a persistent decrease in the symptoms over a period of time.<sup>2</sup> Long term effects of Covid

-19 are also referred as post COVID condition, long COVID, post COVID syndrome etc. While there is still a debate on defining post COVID-19 condition, WHO defines it as , 'an illness that occurs in people who have a history of probable or confirmed SARS-CoV-2 infection; usually three months from the onset of COVID-19, with symptoms and effects that last for at least two months. The symptoms and effects of post COVID-19 condition cannot be explained by an alternative diagnosis.'<sup>6</sup> The Ministry of Health & Family Welfare, Government of India (MOH&FW, GOI) defines post COVID syndrome as a condition characterised by signs and symptoms that develop during or after an infection consistent with COVID-19 which continue for more than 12 weeks and are not explained by alternative diagnosis.<sup>3</sup>

While the Government of India, had framed guidelines for management of post Covid sequelae, there are very scarce data available from Indian context to understand the burden



Please Scan this QR Code to

View this Article Online

Article ID: 2023:03:03:07

Corresponding Author : Sudharshini Subramaniam

e-mail: sudharshini.subramaniam90@gmail.com

of long Covid among Survivors of Covid -19.<sup>3</sup> A standing parliamentary committee headed by Lok Sabha member PP Chaudhury, has suggested the Union Government to take up studies on long term impact of Covid -19 in India.<sup>4</sup> This gives the sense of a dire need for estimating the burden of Long covid effects among survivors of Covid -19 post 2 years of infection. However, the long-term effect of the Covid-19 infection among the survivors has been studied in Tamil Nadu piecemeal. In a study done by ICMR among hospitalised patients with COVID-19 found that Dyspnoea, fatigue and mental health issues as the common post common conditions reported at the end of 1 year follow up and this also reported 4.3% death within 60 days post discharge. The study also compared the three waves of the pandemic and found that the post- discharge death before the first follow-up was highest among the patients admitted during the third wave of COVID-19.<sup>5</sup> This study was done only among hospitalised patients and did not have any information about non-hospitalised patients. In another study conducted to find the burden of post COVID\_19 condition during the 12-14 post recovery period of COVID-19 in Chennai, Tamil Nadu, reported 24% to have post covid symptoms. However, this study was done only within 12-14 week recovery period and included only patients from Chennai.<sup>6</sup> To overcome these gaps, a cross-sectional study was conducted among patients who tested positive for Covid -19 between March 2020 – February 2022 to find the burden of post Covid-19 condition in Tamil Nadu other than Chennai.

## METHODS

A cross sectional study covering population infected at different time interval after Covid infection from March 2020- 31st March, 2022 in Tamil Nadu other than Chennai was done. The study was conducted in the month of July 2023. Assuming 50% variability, and 95% confidence level and 5% absolute precision, the required sample size is 384. To get the result stratified across different time interval post Covid infection starting from 1 year to 3 years post covid irrespective of the severity of infection, the sample size was corrected. To account for non-response rate of 30%, the corrected sample size is 1492, which was rounded off to 1500. However, 1673 patients was included in the survey. In Tamil Nadu, RT-PCR was the only method of testing for diagnosing Covid -19. The line list of RT-PCR positive cases with their contact numbers is updated in the Directorate of Public Health & Preventive Medicine. The line list of all Covid -19 infection who tested positive from March 2020 – 31st March 2022 was obtained to form the sampling frame,

from which the required sample size was randomly selected by stratified random sampling method. The list was stratified into 5 different age groups, <30years, 31-45 years, 46-60 years, 61-75 years, >75 years. The necessary sample from each age group was obtained based on population proportion to size . All the selected individuals were contacted by the trained health staff of the respective district through phone using the contact details available. For those participants, who could not be contacted through phone, the field health workers attempted to visit them in person in the given address. Participants were explained about the purpose of study using a standard transcript which was read by the health staff and verbal consent obtained for participating in the study. Those who give consent were interviewed using a semi- structured questionnaire. Data collection was done by trained health staff who were trained adequately on the study protocol, obtaining consent, interviewing using the semi-structured questionnaire. Details regarding demographic profile , history related to Covid -19 infection and vaccination, co-morbidities and post Covid symptoms were obtained. The operational definition for persistent Post COVID-19 symptoms is the presence of clinical symptoms that developed during or after an infection consistent with COVID-19, persistent for more than 12 weeks. The list of post covid-19 symptoms were taken from the meta-analysis done by Leon et al which reported on the various long term effects.<sup>7</sup>The patients were grouped based on the date of their latest infection with respect to the three waves of the pandemic, considering first wave from the beginning of the pandemic until 1 February 2021, second wave from 2 February 2021 until 15 December 2021, and the third wave from 16 December 2021 to 31 March 2022.




Figure 1. Covid Pandemic Waves in Tamil Nadu

Source: Office of Directorate of Public Health and Preventive Medicine

Symptoms are presented as frequency and proportions, while continuous data are presented as mean (SD) or median (IQR), as appropriate. The frequency of post COVID symptoms was also segregated by the three waves of the pandemic, corresponding to alpha, delta and omicron wave. Odds ratio (OR) with 95% confidence interval (95% CI) for the association between hospitalization, severity of infection , pandemic wave, vaccination and persistent symptoms. Data

analysis was carried out using JASP software.

## RESULTS

Among 1673 patients approached, 380 participants could not be contacted even after multiple attempts. Among the rest 1293 patients, seventy three patients(5.6%) were reported to have died. The demographic profile of the deceased patients is given in table 4. The mean age of the study participants was 41.1 years (SD -17.2 years) with age ranging from 1 year to 90 years. Table 1 gives details about the demographic profile and Covid-19 infection of 1220 patients who responded to the survey. Larger proportion of the study participants reported infection in the 2nd wave and around 41% had hospitalization history. Around seven percentage of study participants reported to have repeated covid infection.

Table 1. Demographic and Covid -19 infection related details of the study participants(n- 1220)

Variable	Frequency	Proportion
Age Group	1-10	30 (2.5%)
	11-20	103 (8.4%)
	21-30	235 (19.3%)
	31-40	268 (22.0%)
	41-50	211 (17.3%)
	51-60	203 (16.6%)
	61-70	115 (9.4%)
	71-80	41 (3.4%)
	81-90	14 (1.1%)
Gender	Male	690 (56.6%)
	Female	530 (43.4%)
Education Status	Illiterate	130 (10.7%)
	1 <sup>st</sup> -5 <sup>th</sup> standard	131 (10.7%)
	6 <sup>th</sup> -10 <sup>th</sup> standard	267 (21.9%)
	Higher Secondary	215 (17.6%)
	Graduate	414 (33.9%)
Latest infection Pandemic Wave	1 <sup>st</sup> wave	301 (24.6%)
	2 <sup>nd</sup> wave	724 (59.3%)
No of episodes of Covid 19 infection	1	1134 (93%)
	>1	86 (7%)
Hospitalization for Covid -19	507	41.6%
Oxygen requirement	106	8.6%
Ventilatory support	18	1.4%
Lung involvement as radiological finding	213	17.5%
Covid -19 Vaccination with at least 1 dose	1056	86.6%
Single dose vaccination	72	5.9%
Two dose vaccination	786	64.4%
Booster dose vaccination	197	16.1%

Table 2 gives the comorbidity profile among study participants. The most common comorbidity prevalent among participants was diabetes and hypertension. With regards to arrhythmia, cancer, cardiac failure and avascular necrosis of femur, more than 50% were reported after Covid-19 infection.

Table 2. Comorbidities among the study participants(n- 1220)

Comorbidities	Before Covid 19		Incidence After Covid 19		
	Frequency (n=1220)	Percent (%)	Frequency (n=1220)	Percent (%)	Percent (%)
Diabetes Mellitus	189	15.5	158	13	2.9
Hypertension	166	13.6	140	11.5	2.4
COPD / Bronchial asthma	24	2	17	1.4	0.6
Chronic Kidney Disease	14	1.1	11	0.9	0.2
Dyslipidaemia	30	2.5	20	1.6	0.8
Thyroid disorders	31	2.5	24	2	0.6
Myocardial Infarction	28	2.3	17	1.4	0.9
Cardiac Failure	6	0.5	2	0.2	0.3
Arrhythmia	10	0.8	5	0.4	0.4
Stroke	14	1.1	8	0.7	0.5
Avascular necrosis	8	0.7	1	0.1	0.6
Cancer	23	1.9	10	0.8	1.1




Figure 1: Among patients with comorbidities, proportion reported post Covid -19 infection

The overall prevalence of persistent post Covid symptoms was 21.3%(95% CI -19.04% - 23.72%). The most common symptom reported was loss of appetite and persistent fatigue.




Figure 2: Post Covid Symptomology (N-1220)

Table 3 shows that there is no significant association between gender, age group, pandemic wave, number of episodes of covid infection, covid vaccination and persistent post covid symptoms. However, hospitalisation, oxygen requirement, ventilatory support requirement, lung involvement and presence of any comorbidities was significantly associated with persistent post covid syndrome.

Table 3. Prevalence of Post Covid -19 by demographic profile and Covid 19 infection

Variable	Post-Covid-19 symptoms n (%)	OR (95% CI)	p-value	
Gender	Male(n-690) Female(n-530)	140(20.3%) 120(22.6%)	1.149(0.8731-1.5143)	0.320
Age group	<18 years 18-45 years 46-60 years >60 years	14(15.1%) 121(18.8%) 76(24.2%) 49(28.8%)	Not applicable	0.08
Pandemic wave	1 <sup>st</sup> wave 2 <sup>nd</sup> wave 3 <sup>rd</sup> wave	67 (22.25%) 149 (20.58%) 44 (22.56%)	Not applicable	0.750
No of episodes of Covid infection	One episode More than 1 episode	238(20.9%) 22(25.5%)	1.294(0.781-2.144)	0.317
Hospitalisation	Yes No	136(26.8%) 124(17.4%)	1.741(1.321- 2.294)	<0.001
Oxygen requirement	Yes No	36 (33.9%) 224 (20.10%)	2.043(1.332- 3.134)	<0.001
Ventilatory support	Yes No	8(44.4%) 252(20.9%)	3.015(1.178-7.720)	0.021
Lung Involvement	Yes No	72(33.8%) 188(18.6%)	2.224(1.607-3.079)	<0.001
Covid Vaccination	Yes No	224(21.2%) 36(21.9%)	0.957(0.642-1.425)	0.829
Presence of comorbidities before covid 19	Diabetes Mellitus No diabetes Hypertension No Hypertension COPD / asthma No COPD/Asthma CKD No CKD Dyslipidaemia No dyslipidaemia Thyroid disorders Normal thyroid Mvocardial Infarction No MI Cardiac Failure No Cardiac Failure Arrythmia No Arrythmia Stroke No Stroke Avascular necrosis No AVN Cancer No Cancer	52(27.5%) 208(20.2%) 60(36.1%) 200(19%) 12(50%) 248(20.7%) 9(64.3%) 251(20.8%) 19(63.3%) 241(20.3%) 15(48.4%) 245(20.6%) 18(64.3%) 242(20.3%) 6(100%) 254(20.9%) 7(70%) 253(20.9%) 10(71.4%) 250(20.7%) 8(100%) 252(20.8%) 6(85.7%) 254(20.9%)	1.519(1.047-2.203) 2.372(1.638-3.434) 3.348(1.528-7.335) 10.33(3.647 -29.274) 8.034(3.563-18.117) 3.673(1.748-7.717) 12.078(4.741 -30.771) 15.647(3.301-74.167) 4.549(1.514-13.662) 6.815(1.978-23.475) 13.792(2.846-66.82) 7.798(1.936-31.410)	0.024 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 0.006 <0.001 <0.001 0.003

Table 4. Age profile of deceased patients among the selected participants

Age group	survived	death	Age specific mortality rate (%)
01-10 years	30	0	0
11-20 years	103	1	0.9%
21-30	235	2	0.8%
31-40	268	2	0.7%
41-50	211	10	4.5%
51-60	203	18	8.1%
61-70	115	27	19.0%
71-80	41	11	21.1%
81-90	14	2	12.5

## DISCUSSION

The findings of this study provide valuable insights into the prevalence and factors associated with persistent post-COVID symptoms, underscoring the need for comprehensive understanding and management of long-term COVID-19 effects. The documented prevalence rate of 21.3% highlights the significant impact of persistent post-COVID symptoms on a substantial portion of the affected population. These symptoms are present even after 1 year past the infection. In a study conducted by Kumar et al among those who required hospitalisation following Covid 19 infection in India, 31% reported to have symptoms in the 30-60 day follow up period.<sup>5</sup> In another study done in Tamil Nadu, 24% reported persistent symptoms during the 12-14 weeks post recovery

period of COVID-19.<sup>6</sup> In another cross sectional study conducted among health care workers with Covid-19 history, the prevalence of COVID sequelae was found to be 30.34% after 12-52 weeks of their discharge.<sup>8</sup> While these studies have looked at a shorter follow up time, in the current study the minimum duration since the last infection was 1 year and the maximum was 3 years. Hence, the prevalence of persistent Covid symptoms could be low compared to the other studies. However, one fifth of the patients still continuing to report at least one of the symptoms even after a long recovery period, indicates the long term effect of Covid -19.

Among the selected study participants, 5.6% was reported to have died. The age specific mortality rate was following the rates in general population.<sup>9</sup> In fact, there was no death reported among the vulnerable children age group between 1-10 years of age.

The most common symptom reported in this study was loss of appetite and persistent fatigue, followed by joint pain/swelling and anxiety. Fatigue was the most common symptom reported in other studies as well.<sup>5,7,10</sup> While the other studies have reported dyspnoea as one of the most commonly reported symptom, it was not the most common symptom in our study. The symptom wise prevalence ranged from 0.3% -4.3%, unlike other studies, where the individual symptoms prevalence was high. Kumar et al reported dyspnoea among 11.9% of patients at end of 100 day follow up.<sup>5</sup> Similarly in the meta-analysis by Leon et al, 58% was the prevalence of fatigue.<sup>7</sup> Fatigue is the most common symptom reported in 17.5-72% of post-COVID cases, followed by residual dyspnoea with an incidence ranging from 10-40%.

The most common comorbidity among the study participants was diabetes and hypertension. However, the concerning incidence rates of arrhythmia, cancer, cardiac failure, and avascular necrosis of the femur reported after COVID-19 infection underscore the wide-ranging and potentially severe complications associated with the virus. A review by Oronsky et al explores underlying mechanisms and possible manifestations of persistent post-COVID syndrome.<sup>11</sup> Among patients with Avascular Necrosis of Femur (AVN) 87.5% reported only after Covid -19 infection. AVN as a possible sequelae of Covid -19 is being reported as many case series and reports are published.<sup>12,13,14,15</sup> Patients with Covid 19 are facing the dual burden of the effect of steroid used as a therapy for Covid-19 and the hypercoagulable state induced by the infection itself, leading to increased risk of AVN.<sup>12</sup> Persistent hypercoagulable state following Covid infection and other factors like production of neutrophil extracellular traps, increased platelet activity,

impaired fibrinolysis and overall decreased anticoagulant function of the endothelium, explains the increased rate of MI and Stroke post covid.<sup>11,16</sup> These findings call for heightened vigilance and tailored follow-up care to monitor and address the increased risk of developing these specific health complications post-COVID-19, further emphasizing the necessity for integrated, multidisciplinary healthcare approaches to manage the diverse long-term sequelae of the disease.

On an attempt to find the factors determining the presence of persistent post covid symptoms, there was no significant difference based on gender. Gender was not a significant factor in other studies as well.<sup>5,6</sup> However, some studies state that female gender had an increased odds of reporting post covid symptoms.<sup>8,17,18</sup> While there was an increasing prevalence of long Covid with increasing age, it was not statistically significant. Advancing age was a significant factor associated with Long Covid in other studies.<sup>5,6,18</sup> There was also no significant difference in the prevalence based on the pandemic wave, whereas in the study by Kumar et al, specific symptoms like dyspnoea, fatigue, and mental health issues were common among those infected in the 2nd wave.<sup>5</sup> There was no difference in the prevalence based on the Covid Vaccination status or the number of episodes of covid infection. Covid vaccination was not increasing the risk of post covid as indicated in other studies.<sup>8,19</sup>

This study showed that patients who had severe Covid as presented as requiring hospitalisation, oxygen or ventilatory support and lung involvement had higher odds of the having COVID sequelae. Similarly, presence of any comorbidity increased the risk of post covid symptoms, emphasizing the critical role of the severity of the initial COVID-19 infection and pre-existing health conditions in influencing long-term health outcomes. This finding demonstrates a high degree of consistency on comparison with studies done in different research context.<sup>6,8,10,18,20,21,22</sup> This finding also highlights the need for targeted management strategies for individuals with these underlying health conditions to mitigate the potential exacerbation of post-COVID.

This study is done among all patients irrespective of their hospitalisation status and the follow up was after a long recovery period extending from 1- 3years post Covid infection. This study had also incorporated the new criterion of persistence of symptoms for at least 3 months as per MOHFW definition of long Covid. However, this study has certain limitations. This was a questionnaire based study and no investigations were carried out to rule out any specific diagnosis. This could impact the reliability of the Persistent

post covid symptom estimate leading to both under and over estimate.

## CONCLUSION

In light of these findings, healthcare professionals and policymakers should prioritize the development of comprehensive post-COVID care protocols that account for the multifaceted nature of persistent post-COVID symptoms and their associated risk factors. By incorporating targeted interventions for individuals with a history of severe COVID-19, pre-existing comorbidities, and specific post-COVID complications, healthcare systems can better support the holistic recovery and well-being of those affected by the long-term effects of the virus. Further research is crucial to unravel the underlying mechanisms driving the persistence of post-COVID symptoms and to inform evidence-based interventions that improve the quality of life for individuals navigating the aftermath of COVID-19.

## ACKNOWLEDGEMENT

We acknowledge all the medical officers and field staff in the district who were involved in the data collection.

## CONFLICT OF INTEREST: Nil

## FUNDING SUPPORT: Nil

## REFERENCES :

1. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):1-12.
2. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Articles Health outcomes in people 2 years after surviving hospitalisation with COVID-19 : a longitudinal cohort study. *The Lancet Respiratory.* 2022;2600(22).
3. Ministry of Health and Family Welfare Government of India. National Comprehensive Guidelines for Management of Post-COVID Sequelae [for doctors].
4. Parliamentary Panel suggests study on long-term Covid effect | Latest News India - Hindustan Times [Internet]. [cited 2022 May 16]. Available from: <https://www.hindustantimes.com/india-news/parliamentary-panel-suggests-study-on-long-term-covid-effect-101648147395307.html>

5. Kumar G, Bhalla A, Mukherjee A, Turuk A, Talukdar A, Mukherjee S, et al. Post COVID sequelae among COVID-19 survivors: insights from the Indian National Clinical Registry for COVID-19. *BMJ Glob Health* [Internet]. 2023 Oct 10;8(10):e012245. Available from: <https://gh.bmj.com/lookup/doi/10.1136/bmjgh-2023-012245>
6. Rubeshkumar P, John A, Narnaware M, M J, Vidya F, Gurunathan R, et al. Persistent Post COVID-19 Symptoms and Functional Status after 12-14 weeks of recovery, Tamil Nadu, India, 2021. *Journal of Infection*. 2022 May;84(5):722–46.
7. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. *Sci Rep* [Internet]. 2021;11(1):1–12. Available from: <https://doi.org/10.1038/s41598-021-95565-8>
8. Shukla AK, Atal S, Banerjee A, Jhaj R, Balakrishnan S, Chugh PK, et al. An observational multi-centric COVID-19 sequelae study among health care workers [Internet]. 2022. Available from: [www.thelancet.com](http://www.thelancet.com)
9. Population Association of America. Trends and Prospects of Mortality by Age and Sex in India: 1991-2030.
10. Iqbal FM, Lam K, Sounderajah V, Clarke JM, Ashrafian H, Darzi A. Characteristics and predictors of acute and chronic post-COVID syndrome: A systematic review and meta-analysis. *EClinicalMedicine*. 2021 Jun;36:100899.
11. Oronsky B, Larson C, Hammond TC, Oronsky A, Kesari S, Lybeck M, et al. A Review of Persistent Post-COVID Syndrome (PPCS). *Clin Rev Allergy Immunol*. 2021 Feb 20;64(1):66–74.
12. Hassan AAA, Khalifa AA. Femoral head avascular necrosis in COVID-19 survivors: a systematic review. *Rheumatol Int*. 2023 Jun 20;43(9):1583–95.
13. Agarwala SR, Vijayvargiya M, Pandey P. Avascular necrosis as a part of 'long COVID-19.' *BMJ Case Rep*. 2021 Jul 2;14(7):e242101.
14. Parikh S, Gomez O, Davis T, Lyon Z, Corces A. Avascular Necrosis as a Sequela of COVID-19: A Case Series. *Cureus*. 2023 Feb;15(2):e35368.
15. Nejadhosseinian M, Haerian H, Tabatabaie Nejad M, Sadeghi K, Aghaghazvini L, Alikhani M, et al. Who is the convict; <sc>COVID</sc> -19 or corticosteroid? Late onset avascular necrosis of hips after <sc>COVID</sc> -19. A case report with literature review. *Int J Rheum Dis*. 2023 Oct 23;26(10):2069–72.
16. Caldeira D, Pinto FJ. COVID-19 and myocardial infarction. *The Lancet*. 2021 Nov;398(10315):1963–4.
17. Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mulè G, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. *Clinical Microbiology and Infection*. 2022 Apr;28(4):611.e9-611.e16.
18. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. *PLoS Med*. 2021 Sep 28;18(9):e1003773.
19. Wynberg E, Han AX, Boyd A, van Willigen HDG, Verveen A, Lebbink R, et al. The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study. *Vaccine*. 2022 Jul 30;40(32):4424–31.
20. Monzon ELA, Li KL. Incidence of post-COVID-19 syndrome and its association with COVID-19 severity in a tertiary private hospital: Prospective cohort study. *IJID Regions*. 2023 Dec;9:14–7.
21. Uniyal N, Sethi Y, Sharma PC, Sayana A, Jeet N, Agarwal A, et al. Post-COVID Syndrome and Severity of COVID-19: A Cross-Sectional Epidemiological Evaluation From North India. *Cureus*. 2022 Jul;14(7):e27345.
22. Bahmer T, Borzikowsky C, Lieb W, Horn A, Krist L, Fricke J, et al. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. *EClinicalMedicine*. 2022 Sep;51:101549.